Tempus AI vs. Guardant Health: Oncology Patent Battle Transferred to Northern District

Case Overview

The Parties

The Patents at Issue

Tempus AI asserted four U.S. patents in this action:

• • US12112839B2 (App. No. US18/188443)
• • US10957041B2 (App. No. US16/830186)
• • US10991097B2 (App. No. US16/732242)
• • US11640859B2 (App. No. US16/771451)

These patents broadly relate to oncology diagnostic technologies, including computational methods for analyzing tumor-derived genomic data — a foundational layer of liquid biopsy and tissue-based cancer testing platforms.

The Verdict & Legal Analysis

Outcome

The California Southern District Court **transferred this case to the Northern District of California**. No damages were awarded, no injunction was issued, and no merits determination was reached at this stage. The transfer constitutes the sole disposition at the first-instance level.

Venue Transfer Analysis

Under **28 U.S.C. § 1404(a)**, a district court may transfer a civil action to another district where it might have been brought, considering convenience of parties, witnesses, and the interests of justice. In patent cases involving technology companies with principal operations in a specific district, courts weigh:

• Location of the accused infringer’s operations — Guardant Health’s headquarters and R&D activities are in the Northern District
• Witness and evidence concentration — technical witnesses, source code, and clinical testing records likely situated in Northern California
• Judicial resources and familiarity — the Northern District of California has extensive experience with diagnostics and genomics patent litigation

The transfer strongly suggests that Guardant Health mounted a timely and persuasive § 1404(a) motion, successfully arguing that the Northern District was the more appropriate forum. Tempus AI’s initial venue selection in the Southern District may reflect a strategic attempt to litigate outside Guardant’s geographic stronghold — a tactic that did not withstand challenge here.

Legal Significance

While no merits ruling exists yet, the venue transfer carries meaningful legal significance:

• Venue selection strategy in patent cases is increasingly scrutinized following TC Heartland LLC v. Kraft Foods Group Brands LLC (2017), which tightened proper venue standards under 28 U.S.C. § 1400(b). Plaintiffs must balance proper venue with strategic forum preferences carefully.
• The Northern District of California will now preside over claim construction of four genomic analysis patents — an analytical exercise that will define the scope of protection for Tempus AI’s oncology IP and determine the infringement exposure for Guardant Health’s product suite.
• The patent portfolio itself — spanning applications filed between 2019 and 2023 — covers technology at the intersection of AI-assisted analysis and liquid biopsy diagnostics, a rapidly evolving and commercially contested space.

Strategic Takeaways

• For Patent Holders: Venue selection must be grounded in defensible connections to the chosen forum. Filing in a district lacking strong ties to either party or accused products creates vulnerability to early transfer motions that can delay substantive proceedings by months.
• For Accused Infringers: A promptly filed § 1404(a) transfer motion — before substantial litigation activity occurs in the original forum — remains one of the most cost-effective early defense strategies in patent cases.
• For R&D Teams: The breadth of accused products here, spanning liquid biopsy to tissue-based testing to real-world data platforms, illustrates that platform-level patent assertions can simultaneously threaten an entire product portfolio. Freedom-to-operate (FTO) analysis should encompass adjacent computational and analytical method patents, not just core diagnostic claims.